Back to Journals » OncoTargets and Therapy » Volume 6

Profile of panobinostat and its potential for treatment in solid tumors: an update

Authors Anne M, Sammartino D, Barginear MF, Budman D

Received 12 July 2013

Accepted for publication 20 August 2013

Published 15 November 2013 Volume 2013:6 Pages 1613—1624


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 5

Madhurima Anne,1 Daniel Sammartino,2 Myra F Barginear,1 Daniel Budman1

1Monter Cancer Center, Hofstra North Shore-LIJ School of Medicine, Lake Success, NY, USA; 2Department of Medicine, Hofstra North Shore-LIJ School of Medicine, Lake Success, NY, USA

Abstract: The histone deacetylase (HDAC) inhibitors have emerged as novel therapies for cancer. Panobinostat (LBH 589, Novartis Pharmaceuticals) is a pan-deacetylase inhibitor that is being evaluated in both intravenous and oral formulations across multiple tumor types. Comparable to the other HDACs, panobinostat leads to hyperacetylation of histones and other intracellular proteins, allowing for the expression of otherwise repressed genes, leading to inhibition of cellular proliferation and induction of apoptosis in malignant cells. Panobinostat, analogous to other HDAC inhibitors, also induces apoptosis by directly activating cellular death receptor pathways. Preclinical data suggests that panobinostat has inhibitory activity at nanomolar concentrations and appears to be the most potent clinically available HDAC inhibitor. Here we review the current status of panobinostat and discuss its role in the treatment of solid tumors.

Keywords: panobinostat, LBH589, histone deacetylase inhibitor, solid tumors

Creative Commons License © 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.